Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies

BACKGROUND: While response rates to anti-PD1 therapy are low in unselected metastatic castration resistant prostate cancer (mCRPC) patients, those with inactivating mutations in mismatch repair (MMR) genes (i.e. MMR deficiency; MMRd) or microsatellite instability (MSI) are thought likely to respond...

Descripción completa

Detalles Bibliográficos
Autores principales: Graham, Laura S., Montgomery, Bruce, Cheng, Heather H., Yu, Evan Y., Nelson, Peter S., Pritchard, Colin, Erickson, Stephanie, Alva, Ajjai, Schweizer, Michael T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250457/
https://www.ncbi.nlm.nih.gov/pubmed/32453797
http://dx.doi.org/10.1371/journal.pone.0233260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250457/
https://www.ncbi.nlm.nih.gov/pubmed/32453797
http://dx.doi.org/10.1371/journal.pone.0233260

Ejemplares similares